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Thyroid carcinoma is an uncommon form of human cancer, with an outstanding overall cure rate. This
excellent prognosis is based on the fact that well over 99% of thyroid cancers are primary tumors.
Metastatic cancer to the thyroid remains very rare. We report a case of clear cell renal carcinoma
metastatic to the thyroid gland 23 years after nephrectomy.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
We review a unique case of metastatic renal cell carcinoma to
the thyroid 23 years after nephrectomy. The discussion will include
a review metastatic renal cell carcinoma.
Case presentation
Our patient is a 78-year-old woman with a left thyroid nodule.
She is asymptomatic, euthyroid, and has no history of thyroid dis-
ease. Her only surgical history was a right nephrectomy 23 years
ago, for a clear cell carcinoma, 4.6 cm in size, low grade (Fuhrman I),
and without vascular, lymphatic, or capsular invasion.
The patient’s medical and family histories are negative. On
physical examination, neck examination revealed a 4.5-cm, soft,
well-circumscribed nodule replacing the left lobe of the thyroid.
There was no lymphadenopathy. Ultrasonographic examination
showed 4.4-cm and 0.7-cm nodules in the left thyroid lobe and two
1.6-cm nodules in the right thyroid lobe.
Fine needle aspiration was performed. Although the cellularity
and monomorphic cell population were consistent with a
neoplastic process, the characteristic features of primary thyroidBY-NC-ND license (http://
dez).
Published by Elsevier Inc. All righneoplasm were lacking. The constellation of cytologic features was
in favor of metastatic renal cell carcinoma. The lesional cells were
focally positive for renal cell carcinoma (RCC) and negative for
thyroid transcription factor-1 (TTF-1) immunostains.
Once the clinical diagnosis of late metastatic RCC was
established by cytopathology, the patient underwent total thy-
roidectomy. The left lobe was markedly enlarged and replaced by
the nodule, with an intact capsule. The right lobewas normal in size
with multiple small nodules. The thyroid was not adherent to any
surrounding structures, and there was no lymphadenopathy.
Gross pathologic examination of the specimen revealed a
markedly enlarged left lobe. Cut section revealed an extensively
hemorrhagic mass with golden-orange speckles of friable tissue,
akin to the conventional clear cell RCC seen in nephrectomy spec-
imens (Fig. 1). Histologic examination showed a well-deﬁned
distinction between the tumor cells and the adjacent thyroid
gland. The tumor showed nests of clear cells separated by a rich
capillary network, which is the classic architecture and cellular
morphology of clear cell RCC (Fig. 2). A more extensive panel of
immunostains appropriately highlighted the renal origin of the
tumor cells by strong positivity for RCC (Fig. 3) and CD10 as well as
negativity for TTF-1, a pattern in sharp contrast with the neigh-
boring thyroid parenchyma.
Discussion
Thyroid nodules are quite common, occurring in up to 50% of the
population, as indicated by ultrasonography. Only about 5% of thesets reserved.
Figure 1. Large hemorrhagic mass with focal golden yellow discoloration, similar to
conventional renal cell carcinoma.
Figure 3. Strong diffuse labeling of tumor with renal cell carcinoma marker, high
power.
C. Valdez et al. / Urology Case Reports 2 (2014) 129e130130nodules are thyroid cancer. Primary thyroid carcinoma increased
from 1% to almost 3% over the past 20 years with the advent of
extensive imaging of the head and neck, with incidental discovery
of thyroid nodules.1 Although metastatic disease to the thyroid
gland is rare, when it does occur kidney is the most common pri-
mary tumor site.2 Other primary sites include melanoma, lung,
breast, esophagus, and uterus; our senior author reported a rare
case ﬁnding of colon cancer metastasis to the thyroid.3
This report describes a tumor arising from the renal paren-
chyma; a clear cell carcinoma, which accounts for 70%-80% of all
renal carcinomas. One of the common characteristics of clear cell
carcinoma is its tendency tometastasizewidely before giving rise to
any local symptoms. In addition to the common sites, metastases
from renal cancer can occur virtually anywhere in the body,
including the thyroid.
When renal cell cancers recur, about 60% recur within 2 years,
70% within 3 years, 80% within 4 years, and most of the rest within
5 years. Recurrences can, however, occur many years later. It hasFigure 2. Nests of clear cells traversed by a rich capillary network, hematoxylin and
eosin, medium power.been reported that 4%-11% of patients develop a recurrence 10 years
after initial nephrectomy.4
The prognosis after surgical excision of clear cell tumors varies
with the size of the tumor, the Fuhrman grade, and the pathologic
stage. Overall, approximately 20%-50% of patients will develop
metastatic disease after nephrectomy.5 However, clear cell cancers
<5 cm in size, low grade (Fuhrman 1), and completely resected,
carry an excellent prognosis with a recurrence rate of<5%. This was
the prognosis for our patient based on her original pathology
23 years ago.
In a 10-year review of 43 patients with metastatic disease to the
thyroid gland at the Mayo clinic, Nakhjavani2 identiﬁed the kidney
as the most common primary tumor site (33%), with an average
time from diagnosis of the primary tumor to metastasis to the
thyroid gland of 106 months. After a thorough review of the English
scientiﬁc literature, we were not able to ﬁnd a longer interval than
our patient (23 years) from initial diagnosis of renal carcinoma to
metastasis to the thyroid gland. There is no useful guidance in the
literature on the extent of thyroidectomy for metastatic disease. In
our case, we chose total thyroidectomy because our patient also had
nodules within the contralateral lobe.Conclusion
High-quality cytopathology services have become extremely
important in themanagement of thyroid nodules. Needle aspiration
is an accurate, quick, and low-risk technique that may yield inter-
esting results such as in this case. This technique served our patient
well in identifying the rare ﬁnding of metastatic RCC to the thyroid
23 years after initial diagnosis.References
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